Results for tag: "Tymlos"

The Tymlos market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat osteoporosis, a condition characterized by low bone density and increased risk of fractures. Tymlos is a brand of medication that contains the active ingredient abaloparatide, a synthetic form of parathyroid hormone. It is used to increase bone mineral density and reduce the risk of fractures in postmenopausal women with osteoporosis. Tymlos is a relatively new drug, having been approved by the US Food and Drug Administration in 2017. It is administered as a daily subcutaneous injection and is typically used in combination with other osteoporosis medications. Some companies in the Tymlos market include Radius Health, Inc., which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the medication. Additionally, there are numerous distributors and retailers that supply the drug to patients. Show Less Read more